Clinical trial
Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small…
NCT00323869 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00323869 |
|---|---|
| Title | Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer |
| Official title | Phase II Trial of Bevacizumab in Combination With Gemcitabine and Carboplatin in Patients With Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell Carcinoma) |
| Lead sponsor | Stanford University, Other |
| Collaborators | Eli Lilly and Company Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Non-small Cell Lung Cancer (NSCLC) |
| Intervention type | Drug |
| Interventions | Bevacizumab, Gemcitabine, Carboplatin |
| Enrollment | 48 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2013 |
| Completion | Oct 1, 2013 |
| First posted | May 10, 2006 |
| Last update posted | Sep 7, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: